Reply to 'Rituximab in CD20 positive multiple myeloma' by P Moreau et al. [10]

Leukemia

Volumn 22, Issue 1, 2008, Pages 214-215

  Greipp, P T ^a   Kapoor, P ^a   Morice, W G ^a   Witzig, T E ^a   Greipp, P R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; CYCLIN D1; IMMUNOGLOBULIN A; RITUXIMAB;

AGED; ANTIGEN EXPRESSION; BONE MARROW CELL; CANCER CONTROL; CASE REPORT; DRUG FEVER; DRUG RESPONSE; DRUG TOLERABILITY; EXERCISE; FATIGUE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LETTER; MAINTENANCE THERAPY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; PHENOTYPE; PRIORITY JOURNAL; RIGOR;

EID: 38349057298     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404972     Document Type: Letter

References (5)

1. Moreau P, Voillat L, Benboukher L, Mathiot C, Dumontet C, Robillard N et al. Rituximab in-CD20 positive multiple myeloma. Leukemia 2007; 21: 835-836.
2. Robillard N. Avet-Loiseau H, Garand R, Moreau P, Pineau D. Rapp MJ et al. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood 2003; 102: 1070-1071.
3. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y et al Characterization bf clonogenic multiple myeloma cells. Blood 2004; 103: 2332-2336.
4. Fonseca R, Blood EA, Oken, MM, Kyle RA, Dewald GW, Bailey RJ et al Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood 2002; 99: 3735-3741.
5. Robillard N, Wuilleme S, Lode L, Magrangeas, F, Minvielle S, Avet-Loiseau H. CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target. Leukemia 2005; 19: 2021-2022.